Literature DB >> 21086759

Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways.

Sami J Barmada1, Steven Finkbeiner.   

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are late-onset neurodegenerative disorders that are associated with mutations in the TARDBP gene. The product of this gene, TDP-43, has also been identified as the main component of the intracellular inclusions typical of most cases of ALS and FTD. Recent evidence suggests that TDP-43 is essential for proper development and involved in several fundamental cellular processes, including gene transcription, RNA processing, and the spatial regulation of mRNA translation. Pathogenic TARDBP mutations that impair TDP-43 function could therefore be related to neuronal degeneration in ALS and FTD. Conversely, cellular and animal studies have shown that pathogenic TARDBP mutations induce neuronal toxicity through mislocalization or elevated concentrations of TDP-43, consistent with a gain-of-function mechanism. In this review, we focus on the physiologic functions of TDP-43 within the central nervous system and discuss how these functions may be perturbed or pathologically altered by disease-associated mutations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21086759     DOI: 10.1515/revneuro.2010.21.4.251

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  29 in total

1.  A new postal code for dendritic mRNA transport in neurons.

Authors:  Carsten Drepper; Michael Sendtner
Journal:  EMBO Rep       Date:  2011-07-01       Impact factor: 8.807

2.  Dysregulation of TDP-43 intracellular localization and early onset ALS are associated with a TARDBP S375G variant.

Authors:  Kathy Newell; Francesca Paron; Miguel Mompean; Jill Murrell; Elisa Salis; Cristiana Stuani; Gary Pattee; Maurizio Romano; Douglas Laurents; Bernardino Ghetti; Emanuele Buratti
Journal:  Brain Pathol       Date:  2018-12-27       Impact factor: 6.508

3.  Molecular dissection of TDP-43 proteinopathies.

Authors:  Masato Hasegawa; Takashi Nonaka; Hiroshi Tsuji; Akira Tamaoka; Makiko Yamashita; Fuyuki Kametani; Mari Yoshida; Tetsuaki Arai; Haruhiko Akiyama
Journal:  J Mol Neurosci       Date:  2011-06-16       Impact factor: 3.444

Review 4.  Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis.

Authors:  Sami J Barmada
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 5.  TDP-43 autoregulation: implications for disease.

Authors:  Mauricio Budini; Emanuele Buratti
Journal:  J Mol Neurosci       Date:  2011-06-18       Impact factor: 3.444

6.  Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1.

Authors:  Sami J Barmada; Shulin Ju; Arpana Arjun; Anthony Batarse; Hilary C Archbold; Daniel Peisach; Xingli Li; Yuxi Zhang; Elizabeth M H Tank; Haiyan Qiu; Eric J Huang; Dagmar Ringe; Gregory A Petsko; Steven Finkbeiner
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

7.  Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region.

Authors:  Mauricio Budini; Emanuele Buratti; Cristiana Stuani; Corrado Guarnaccia; Valentina Romano; Laura De Conti; Francisco E Baralle
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

Review 8.  TDP43 and RNA instability in amyotrophic lateral sclerosis.

Authors:  Kaitlin Weskamp; Sami J Barmada
Journal:  Brain Res       Date:  2018-01-31       Impact factor: 3.252

Review 9.  Mouse models of frontotemporal dementia.

Authors:  Erik D Roberson
Journal:  Ann Neurol       Date:  2012-12       Impact factor: 10.422

10.  Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion.

Authors:  Lei-Lei Jiang; Mei-Xia Che; Jian Zhao; Chen-Jie Zhou; Mu-Yun Xie; Hai-Yin Li; Jian-Hua He; Hong-Yu Hu
Journal:  J Biol Chem       Date:  2013-05-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.